NO328983B1 - Anvendelse av pegylert interferon alfa for fremstilling av et medikament for behandling av en pasient med renalt cellekarsinom. - Google Patents

Anvendelse av pegylert interferon alfa for fremstilling av et medikament for behandling av en pasient med renalt cellekarsinom. Download PDF

Info

Publication number
NO328983B1
NO328983B1 NO20014851A NO20014851A NO328983B1 NO 328983 B1 NO328983 B1 NO 328983B1 NO 20014851 A NO20014851 A NO 20014851A NO 20014851 A NO20014851 A NO 20014851A NO 328983 B1 NO328983 B1 NO 328983B1
Authority
NO
Norway
Prior art keywords
pegylated interferon
interferon alfa
patient
use according
treatment
Prior art date
Application number
NO20014851A
Other languages
English (en)
Norwegian (no)
Other versions
NO20014851D0 (no
NO20014851L (no
Inventor
Mary Ellen Rybak
Esther Helen Rose
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20014851D0 publication Critical patent/NO20014851D0/no
Publication of NO20014851L publication Critical patent/NO20014851L/no
Publication of NO328983B1 publication Critical patent/NO328983B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
NO20014851A 1999-04-08 2001-10-05 Anvendelse av pegylert interferon alfa for fremstilling av et medikament for behandling av en pasient med renalt cellekarsinom. NO328983B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28835999A 1999-04-08 1999-04-08
PCT/US2000/009127 WO2000061174A2 (en) 1999-04-08 2000-04-06 Use of pegylated interferon alpha for renal cell carcinoma treatment

Publications (3)

Publication Number Publication Date
NO20014851D0 NO20014851D0 (no) 2001-10-05
NO20014851L NO20014851L (no) 2001-12-07
NO328983B1 true NO328983B1 (no) 2010-07-05

Family

ID=23106761

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014851A NO328983B1 (no) 1999-04-08 2001-10-05 Anvendelse av pegylert interferon alfa for fremstilling av et medikament for behandling av en pasient med renalt cellekarsinom.

Country Status (23)

Country Link
EP (2) EP1043025B1 (cg-RX-API-DMAC7.html)
JP (2) JP4721488B2 (cg-RX-API-DMAC7.html)
CN (1) CN1367702A (cg-RX-API-DMAC7.html)
AR (1) AR029160A1 (cg-RX-API-DMAC7.html)
AT (2) ATE419002T1 (cg-RX-API-DMAC7.html)
AU (2) AU777406B2 (cg-RX-API-DMAC7.html)
BR (1) BR0009644A (cg-RX-API-DMAC7.html)
CA (1) CA2303752A1 (cg-RX-API-DMAC7.html)
CO (1) CO5170412A1 (cg-RX-API-DMAC7.html)
CY (1) CY1108919T1 (cg-RX-API-DMAC7.html)
DE (2) DE60041291D1 (cg-RX-API-DMAC7.html)
DK (2) DK1043025T3 (cg-RX-API-DMAC7.html)
ES (2) ES2239953T3 (cg-RX-API-DMAC7.html)
HU (1) HU230271B1 (cg-RX-API-DMAC7.html)
MX (1) MXPA00003401A (cg-RX-API-DMAC7.html)
MY (1) MY155221A (cg-RX-API-DMAC7.html)
NO (1) NO328983B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ514629A (cg-RX-API-DMAC7.html)
PE (1) PE20010026A1 (cg-RX-API-DMAC7.html)
PT (2) PT1535623E (cg-RX-API-DMAC7.html)
TW (2) TWI310314B (cg-RX-API-DMAC7.html)
WO (1) WO2000061174A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200108169B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR029160A1 (es) * 1999-04-08 2003-06-18 Schering Corp El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
US20070231301A1 (en) * 2006-03-31 2007-10-04 Warren Stephen L Parenteral low dose type 1 interferons for bladder cancer
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8053430B2 (en) 2008-10-06 2011-11-08 Haraldsson Boerje Treatment of renal cell carcinoma
EP2552443B1 (en) 2010-04-01 2021-07-14 Oncorena Ab Improved treatment of renal cell carcinoma
CN103463623B (zh) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法
KR102920712B1 (ko) 2017-05-24 2026-01-30 노파르티스 아게 항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
WO2024186735A1 (en) * 2023-03-03 2024-09-12 Memorial Sloan-Kettering Cancer Center Methods and compositions for the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
CA2324467C (en) * 1998-03-26 2002-11-05 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
AR029160A1 (es) * 1999-04-08 2003-06-18 Schering Corp El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo

Also Published As

Publication number Publication date
HK1075417A1 (en) 2005-12-16
EP1535623A1 (en) 2005-06-01
PT1535623E (pt) 2009-03-19
MY155221A (en) 2015-09-30
TW200526243A (en) 2005-08-16
TWI310314B (en) 2009-06-01
JP3712914B2 (ja) 2005-11-02
DE60020442D1 (de) 2005-07-07
EP1043025A3 (en) 2000-12-20
HU230271B1 (hu) 2015-11-30
EP1535623B1 (en) 2008-12-31
JP2001288110A (ja) 2001-10-16
PE20010026A1 (es) 2001-02-05
ATE419002T1 (de) 2009-01-15
NZ514629A (en) 2004-02-27
CN1367702A (zh) 2002-09-04
PT1043025E (pt) 2005-09-30
DK1043025T3 (da) 2005-07-04
NO20014851D0 (no) 2001-10-05
MXPA00003401A (es) 2002-03-08
DE60020442T2 (de) 2006-05-04
ES2239953T3 (es) 2005-10-16
JP2000319196A (ja) 2000-11-21
BR0009644A (pt) 2002-01-08
CO5170412A1 (es) 2002-06-27
DK1535623T3 (da) 2009-04-27
WO2000061174A3 (en) 2001-01-25
HUP0200781A3 (en) 2002-09-30
AU2004242454A1 (en) 2005-01-20
WO2000061174A2 (en) 2000-10-19
DE60041291D1 (de) 2009-02-12
HUP0200781A2 (en) 2002-08-28
AU777406B2 (en) 2004-10-14
CY1108919T1 (el) 2014-07-02
CA2303752A1 (en) 2000-10-08
AR029160A1 (es) 2003-06-18
AU2004242454B2 (en) 2007-02-15
AU4204400A (en) 2000-11-14
EP1043025A2 (en) 2000-10-11
EP1043025B1 (en) 2005-06-01
ES2319777T3 (es) 2009-05-12
JP4721488B2 (ja) 2011-07-13
ZA200108169B (en) 2003-01-06
HK1032533A1 (en) 2001-07-27
ATE296638T1 (de) 2005-06-15
NO20014851L (no) 2001-12-07

Similar Documents

Publication Publication Date Title
US6685931B1 (en) Treatment of hepatitis C virus infections with interleukin-10
US7482014B2 (en) Melanoma therapy
EP1043025B1 (en) Renal cell carcinoma treatment
US6362162B1 (en) CML Therapy
US6605273B2 (en) Renal cell carcinoma treatment
JP2001288110A6 (ja) 腎細胞ガン処置
AU2004242456B2 (en) CML therapy
NO328111B1 (no) Anvendelse av et pegylert interferon alfa-2b for fremstilling av et medikament for behandling av en pasient som har melanom som er blitt kirurgisk fjernet.
HK1075417B (en) Renal cell carcinoma treatment
HK1032533B (en) Renal cell carcinoma treatment
MXPA00003345A (en) Melanoma therapy
HK1032349B (en) Melanoma therapy
HK1032348B (en) Chronic myeloid leukemia (cml) therapy
HK1075418A (en) Chronic myeloid leukemia (cml) therapy

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US

MM1K Lapsed by not paying the annual fees